TrkB promotes laryngeal cancer metastasis via activation PI3K/AKT pathway
Citations Over TimeTop 14% of 2017 papers
Abstract
Our data indicate TrkB are overexpressed in laryngeal cancer, and TrkB signaling is involved in tumorigenicity of laryngeal cancer. These observations suggest that TrkB is a promising target for future intervention strategies to prevent tumor metastasis, EMT program in laryngeal cancer.What is already known about this subject?• Cancer of the larynx is one of the most common types of head and neck cancer.• The survival rate of advanced laryngeal cancer is only 30 to 40%.• The tropomyosin-related kinase B receptor (TrkB), together with TrkA and TrkC, are neurotrophin receptors regulating the proliferation and differentiation of neuronal cells.What are the new findings?• TrkB are overexpressed in laryngeal cancer.• TrkB signaling is involved in tumorigenicity of laryngeal cancer.• TrkB acts as a key regulator of the PI3K/AKT signal pathway-mediated tumor metastasis.How might these results change the focus of research or clinical practice?• These observations suggest that TrkB is a promising target for future intervention strategies to prevent tumor metastasis, EMT program in laryngeal cancer. Our study provides molecular insight into the tumor metastasis and has important implications in elucidating oncogenic processes.
Related Papers
- → Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells(1993)520 cited
- → Gene Expression of Neurotrophins and Their High-Affinity Trk Receptors in Cultured Human Müller Cells(2002)51 cited
- → Structural determinants of Trk receptor specificities using BNDF-based neurotrophin chimeras(1996)4 cited
- → The expression of the TrkA and TrkB high-affinity neurotrophin receptors in the rat hippocampus after intracerebroventricular administration of Aβ(25–35)(2015)
- → Evaluation of microneurotrophins activity on neurotrophins receptors and their role in signalling, in in vitro an in vivo neurodegenerative conditions, such as alzheimer's disease(2023)